

## Special Issue

# COVID-19, Neuroinflammation and Therapeutics, 2nd Edition

### Message from the Guest Editor

With a continuously growing knowledge base due to information gathered from epidemiological studies, randomized controlled trials (RCTs), observational studies, case reports, and meta-analytical reviews, new light has been shed on different aspects of the direct and indirect disease burden associated with COVID-19. Although primarily a disease of the respiratory system, systematic inflammatory and immune responses have also emerged as a result of COVID-19; this indicates that its manifestations are diverse and affect multiple systems, including the nervous system. This Special Issue aims to fill knowledge gaps on COVID-19. We are inviting research papers, including reports, observational studies, RCTs, reviews (including narrative reviews), and meta-analytical reviews, that provide novel insights into the clinical features, treatments, therapeutics, and inflammatory biomarkers of COVID-19 (e.g., through laboratory-, neuroimaging-, or neurophysiology-based approaches). Bringing this new research to the forefront of the scientific community will enhance our understanding of this virus and its effects, especially those related to its neurological complications.

### Guest Editor

Dr. Yasir Rehman

Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada

### Deadline for manuscript submissions

closed (31 October 2024)



## Neurology International

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.8  
Indexed in PubMed



[mdpi.com/si/188905](https://mdpi.com/si/188905)

*Neurology International*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[neurolint@mdpi.com](mailto:neurolint@mdpi.com)

[mdpi.com/journal/  
neurolint](https://mdpi.com/journal/neurolint)





# Neurology International

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.8  
Indexed in PubMed



[mdpi.com/journal/  
neurolint](https://mdpi.com/journal/neurolint)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Junji Yamauchi

1. Laboratory of Molecular Neurology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
2. Department of Pharmacology, National Research Institute for Child Health and Development, Tokyo, Japan

---

#### Author Benefits

##### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

##### High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, and other databases.

##### Journal Rank:

JCR - Q2 (Clinical Neurology)